Nanfang Hospital, Southern Medical University: Leukemia, Myeloid, Acute trials

The registry lists 20 Leukemia, Myeloid, Acute studies with Nanfang Hospital, Southern Medical University as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 2 11Phase 3 10No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical StudyNot yet recruitingNCT07264010Phase 2/3
• HVA vs IA/DA or VA in the Treatment of ND HR-AMLRecruitingNCT06810791Phase 3
• A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction FailureNot yet recruitingNCT05875649
• The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCTStatus unknownNCT05596981
• The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCTStatus unknownNCT05596968
• Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AMLCompletedNCT05456048
• G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCTStatus unknownNCT05449899Phase 2/3
• Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AMLStatus unknownNCT05404516Phase 2
• Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AMLCompletedNCT04788420
• Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAMLCompletedNCT04424147Phase 2
• Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AMLStatus unknownNCT03701217Phase 2/3
• The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AMLStatus unknownNCT03665480Phase 2/3
• Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AMLStatus unknownNCT03642236Phase 2/3
• Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCTStatus unknownNCT03530085Phase 2/3
• Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+CompletedNCT02936089Not applicable
• MRD-directed Therapy for Low-risk and Intermediate-risk AML.CompletedNCT02870777Phase 2/3
• Hematopoietic Stem Cell Microtransplantation for in AMLStatus unknownNCT02676856Not applicable
• IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCTCompletedNCT02671708Phase 2/3
• Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AMLCompletedNCT02474290Phase 2/3
• Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia PatientsStatus unknownNCT01889407